SCHEMBL1531346

SCHEMBL1531346

COC(=O)c1sc(-c2ccc(Cl)cc2)cc1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 1.00
KDM4E B2RXH2 11/20 1.00
RAB9A P51151 6/20 1.00
NPC1 O15118 6/20 1.00
CASP3 P42574 2/20 1.00
SENP8 Q96LD8 2/20 1.00
SENP7 Q9BQF6 2/20 1.00
SENP6 Q9GZR1 2/20 1.00
IKBKB O14920 3/20 0.74
ALDH1A1 P00352 4/20 0.71
POLB P06746 1/20 0.71
KMT2A Q03164 5/20 0.68
MEN1 O00255 4/20 0.68
GAA P10253 1/20 0.68
GFER P55789 1/20 0.68
RXFP1 Q9HBX9 2/20 0.61
NPSR1 Q6W5P4 2/20 0.58
TP53 P04637 3/20 0.58
HPGD P15428 2/20 0.58
HSD17B10 Q99714 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10070140 0.88 MAPT (0.78) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL4096459 0.87 MAPT (0.78) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL5195941 0.87 KDM4E (0.76) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL5370617 0.87 MAPT (0.76) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL1724239 0.85 IKBKB (1.00) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL431794 0.85 MAPT (0.74) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL1143359 0.85 MAPT (0.76) MAPTKDM4ERAB9ANPC1CASP3
Hydrochloric Acid SCHEMBL8864118 0.84 MAPT (0.72) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL12530234 0.84 MAPT (0.72) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL5362627 0.83 MAPT (1.00) MAPTKDM4ERAB9ANPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8986399-B2 Treating lignocellulosic materials EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2015-03-24 US disclosed
EP-1987042-B1 NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI SA (FR) 2015-01-21 EP disclosed
EP-1987042-B1 NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI SA (FR) 2015-01-21 EP disclosed
US-8853208-B2 Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-10-07 US disclosed
US-8853208-B2 Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-10-07 US disclosed
US-8853208-B2 Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-10-07 US disclosed
US-8828991-B2 Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-09 US disclosed
US-8828991-B2 Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-09 US disclosed
US-8828991-B2 Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-09 US disclosed
US-8618115-B2 Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them BRISTOL-MYERS SQUIBB COMPANY (US) 2013-12-31 US disclosed
US-20040220404-A1 Pyrimidinones as melanin concentrating hormone receptor 1 SMITHKLINE BEECHAM P.L.C. (GB) 2004-11-04 US disclosed
WO-2004092181-A1 HETEROCYCLIC MCHR1 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-10-28 WO disclosed
US-20040192943-A1 Nf-kappab inhibitors SMITHKLINE BEECHAM CORPORATION 2004-09-30 US disclosed
EP-1448545-A1 NF-KB INHIBITORS SmithKline Beecham Corporation (US) 2004-08-25 EP disclosed
EP-1442025-A1 PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 SMITHKLINE BEECHAM PLC (GB) 2004-08-04 EP disclosed
US-6583154-B1 Neuropeptide Y antagonist; pyrrolo-(3,2-b)pyridines and pyrrolo-(3,2-d)pyrimidines AMGEN INC. 2003-06-24 US disclosed
WO-2003033476-A1 PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 SMITHKLINE BEECHAM PLC (GB) 2003-04-24 WO disclosed
WO-2003029242-A1 NF-λB INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-04-10 WO disclosed
US-6187777-B1 PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES; NEUROPEPTIDE Y AND CORTICOTROPIN RELEASING FACTOR MODULATORS; DIETETICS; ANTIDIABETIC, ANTIINFLAMMATORY, AND ANTITUMOR AGENTS AMGEN INC. 2001-02-13 US disclosed
EP-0227431-A1 Heterocyclic amides BEECHAM GROUP PLC (GB) 1987-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220404-A1 Pyrimidinones as melanin concentrating hormone receptor 1 MC1R, MCHR1, MCHR2 MAPT 2954/4885KDM4E 4227/4885RAB9A 1491/4885
US-20040192943-A1 Nf-kappab inhibitors NFKBIA, IKBKB, IKBKG MAPT 1500/4885KDM4E 2149/4885RAB9A 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.